Arovella Submits IND Application for First-in-Human Trial of CAR-iNKT Cell Therapy ALA-101
Key Insights
Arovella Therapeutics (search) has submitted an Investigational New Drug application to the FDA for ALA-101, an allogeneic CAR-iNKT cell therapy targeting CD19 (search)-positive non-Hodgkin's lymphoma (search) and leukemias.
The therapy offers potential advantages over first-generation CAR-T approaches, including scalable manufacturing, off-the-shelf dosing, and reduced risk of graft-versus-host disease.
FDA clearance would enable a first-in-human Phase 1 trial planned for early 2026, marking Arovella's transition to clinical-stage biotechnology company.
Arovella Therapeutics (search) Limited has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration for its lead allogeneic CAR-iNKT cell therapy candidate, ALA-101, targeting CD19 (search)-positive non-Hodgkin's lymphoma (search) and leukemias. The submission marks a significant milestone in the company's progression toward becoming a clinical-stage biotechnology company.
Novel CAR-iNKT Platform Technology
ALA-101 represents an innovative approach to cell therapy, utilizing an allogeneic CAR-invariant natural killer T-cell therapy platform engineered to express CD19 (search)-specific CAR as an off-the-shelf product. The therapy is designed to target the CD19 antigen found on various hematological malignancies.
According to Michael Baker, CEO and managing director of Arovella Therapeutics (search), "Filing the [investigational NDA] for ALA-101 is an excellent milestone for Arovella, and we look forward to receiving the feedback from the FDA. It reflects the strength of our scientific and manufacturing foundations and marks the company's transition toward becoming a clinical-stage biotechnology company."
Advantages Over Traditional CAR-T Therapies
The CAR-iNKT platform offers several potential advantages over first-generation CAR-T approaches. The manufacturing process is designed to be scalable and cost-efficient, while the off-the-shelf nature of the therapy could reduce time to treatment for patients and improve access.
A key differentiator is the reduced risk of graft-versus-host disease. As Baker explained, "This means when introduced into a new person's bloodstream, the cells do not recognize anything as foreign and avoid launching an immune attack on the recipient. That is a big advantage and unlocks the potential to use them in what we call an off-the-shelf fashion."
The unique biology of iNKT cells allows for manufactured cells donated from one person to be administered to another, as they target the same universal antigen found in every human. This enables the therapy to be "stockpiled" and ready for use when needed, potentially reducing manufacturing time and delivering therapy to patients faster.
Clinical Development Timeline
FDA clearance of the IND application would enable Arovella to launch a first-in-human Phase 1 trial in relapsed or refractory CD19 (search)-positive blood cancers (search). The FDA typically reviews such applications within 30 days of submission. Trial sites are planned in both Australia and the United States under a more efficient regulatory pathway.
The planned Phase 1 trial will study safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of ALA-101, with plans to begin in early 2026. The IND submission allows for clinical trials to open in the US and enables use of the Clinical Trial Notification scheme for Phase 1 trials, as opposed to the lengthier Clinical Trial Application pathway.
Pipeline Expansion Plans
Arovella has announced plans to expand its ALA platform beyond hematological malignancies. In September 2025, at the Australia Securities Exchange Small and Mid-Cap Conference, Baker announced development of ALA-105, which will target CLDN18.2 (search) for patients with gastric and pancreatic cancer (search). ALA-105 will incorporate IL-12-TM technology to further advance the pipeline.
"Our strategy is to build a portfolio of differentiated cell therapies based on the unique biology of iNKT cells. We believe this platform has the potential to deliver safe, more effective, and more accessible treatments for patients with both blood cancers (search) and solid tumors (search)," Baker stated.
The company has additional plans to continue manufacturing treatments for both hematologic and solid tumor indications, positioning itself in the competitive cell therapy market with its invariant natural killer T (iNKT) cell therapy platform licensed from Imperial College London.